Compare Quest Diagnostics Inc (DGX) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while iShares 3 7 Year Treasury Bond ETF trades at $113.5 (market cap $16.72B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| DGX | IEI | |
|---|---|---|
Market Cap | $25.48B | $16.72B |
Volume | 941,866 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $120.72 |
52-Week Low | $173.49 | $113.17 |
Typical Hold Time | 56 Days | 43 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
IEI trades at $113.465 with minimal daily movement (+0.07%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $114 with support at $113. Recent dividend payments of $0.37-0.38 demonstrate consistent shareholder returns, though key financial ratios remain unavailable for fundamental assessment.
The bearish technical outlook and lack of fundamental data create uncertainty. Bond market volatility and rising Treasury yields present macroeconomic headwinds. Investment potential depends on forthcoming financial disclosures and the company's ability to navigate current interest rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
